» Articles » PMID: 22920906

The Therapeutic Target Hsp90 and Cancer Hallmarks

Overview
Journal Curr Pharm Des
Date 2012 Aug 28
PMID 22920906
Citations 163
Authors
Affiliations
Soon will be listed here.
Abstract

Hsp90 is a major molecular chaperone that is expressed abundantly and plays a pivotal role in assisting correct folding and functionality of its client proteins in cells. The Hsp90 client proteins include a wide variety of signal transducing molecules such as protein kinases and steroid hormone receptors. Cancer is a complex disease, but most types of human cancer share common hallmarks, including self-sufficiency in growth signals, insensitivity to growth-inhibitory mechanism, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. A surprisingly large number of Hsp90-client proteins play crucial roles in establishing cancer cell hallmarks. We start the review by describing the structure and function of Hsp90 since conformational changes during the ATPase cycle of Hsp90 are closely related to its function. Many co-chaperones, including Hop, p23, Cdc37, Aha1, and PP5, work together with Hsp90 by modulating the chaperone machinery. Post-translational modifications of Hsp90 and its cochaperones are vital for their function. Many tumor-related Hsp90-client proteins, including signaling kinases, steroid hormone receptors, p53, and telomerase, are described. Hsp90 and its co-chaperones are required for the function of these tumor-promoting client proteins; therefore, inhibition of Hsp90 by specific inhibitors such as geldanamycin and its derivatives attenuates the tumor progression. Hsp90 inhibitors can be potential and effective cancer chemotherapeutic drugs with a unique profile and have been examined in clinical trials. We describe possible mechanisms why Hsp90 inhibitors show selectivity to cancer cells even though Hsp90 is essential also for normal cells. Finally, we discuss the "Hsp90-addiction" of cancer cells, and suggest a role for Hsp90 in tumor evolution.

Citing Articles

A Practical Approach to Quantitatively Assessing Equilibrium-Constant Accuracy from a Single Binding Isotherm.

Wang T, Latimer J, Rukundo J, Kogan I, Krylova S, Schreiber S Precis Chem. 2025; 3(2):89-104.

PMID: 40018450 PMC: 11863166. DOI: 10.1021/prechem.4c00085.


Inhibiting HSP90 changes the expression pattern of PINK1 and BNIP3 and induces oxidative stress in colon cancer cells.

Abu-El-Rub E, Alzubi A, Almahasneh F, Khaswaneh R, Almazari R, Kasasbeh A Mol Biol Rep. 2025; 52(1):212.

PMID: 39921807 PMC: 11807072. DOI: 10.1007/s11033-025-10303-x.


Novel starting points for fragment-based drug design against human heat-shock protein 90 identified using crystallographic fragment screening.

Huang L, Wang W, Zhu Z, Li Q, Li M, Zhou H IUCrJ. 2025; 12(Pt 2):177-187.

PMID: 39819741 PMC: 11878448. DOI: 10.1107/S2052252524012247.


PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.

Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M Front Pharmacol. 2024; 15:1475998.

PMID: 39564119 PMC: 11573589. DOI: 10.3389/fphar.2024.1475998.


HSP90AA1 is an unfavorable prognostic factor for hepatocellular carcinoma and contributes to tumorigenesis and chemotherapy resistance.

Wang Z, Fan L, Xu H, Qin Z, Zhu Z, Wu D Transl Oncol. 2024; 50():102148.

PMID: 39388959 PMC: 11736399. DOI: 10.1016/j.tranon.2024.102148.


References
1.
Lees-Miller S, Anderson C . Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II. J Biol Chem. 1989; 264(5):2431-7. View

2.
McDowell C, Sutton R, Obermann W . Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol. 2009; 45(3):310-4. DOI: 10.1016/j.ijbiomac.2009.06.012. View

3.
Gray Jr P, Prince T, Cheng J, Stevenson M, Calderwood S . Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer. 2008; 8(7):491-5. PMC: 2779120. DOI: 10.1038/nrc2420. View

4.
Yu X, Guo Z, Marcu M, Neckers L, Nguyen D, Chen G . Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002; 94(7):504-13. DOI: 10.1093/jnci/94.7.504. View

5.
An W, Schulte T, Neckers L . The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000; 11(7):355-60. View